long term use of glp 1 agonists The long-term cardiovascular safety and efficacy glucagon-like peptide-1 (GLP-1) receptor in high-risk cardiovascular populations: a systematic review and meta-analysis | Cardiovascular Diabetology – Endocrinology Reports Glucagon-like peptide-1 receptor: mechanisms and
Description
The difficulty was that testing for low blood glucose necessitated laboratory equipment and technical skills that were then not available to most physicians
The REWIND trial investigated the cardiovascular benefits of dulaglutide, a GLP-1 receptor agonist, in a population of 9,901 patients with T2DM aged 50+ and either established CVD or risk factors
Vendrell J, El Bekay R, Peral B, Garcia-Fuentes E, Megia A, Macias-Gonzalez M, et al
Antibiotics study Antibiotics (ampicillin 1 g/L, neomycin 1 g/L, metronidazole 1 g/L
Treatment of type 2 diabetes with incretin-based therapies
